Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1-adrenergic receptors in vitro

Schizophrenia Research

Volumn 37, Issue 1, 1999, Pages 107-122

  Bymaster, Frank P ^a   Nelson, David L ^a   Delapp, Neil W ^a   Falcone, Julie F ^a   Eckols, Kris ^a   Truex, Lewis L ^a   Foreman, Mark M ^a   Lucaites, Virginia L ^a   Calligaro, David O ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic; Clozapine; Dopamine; Muscarinic; Norepinep hrine; Olanzapine; Psychosis; Schizophrenia

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CARBACHOL; CLOZAPINE; CYCLIC AMP DERIVATIVE; DOPAMINE 1 RECEPTOR; HISTAMINE H1 RECEPTOR; HOMOVANILLIC ACID; OLANZAPINE; OXOTREMORINE; PRAZOSIN; PROMETHAZINE; RECEPTOR SUBTYPE; RISPERIDONE;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL CELL; ANIMAL TISSUE; ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR AFFINITY;

ADENYLATE CYCLASE; ANIMALS; BENZODIAZEPINES; CELLS, CULTURED; CRICETINAE; KINETICS; PIRENZEPINE; RATS; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, DOPAMINE D1; RECEPTORS, HISTAMINE H1; RECEPTORS, MUSCARINIC; RECEPTORS, SEROTONIN; RETINA;

EID: 0033522430     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00146-7     Document Type: Article

References (62)

1. 3H ]-SCH23390 binding in vivo Eur. J. Pharmacol. 120:1986;143-144.
2. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 18:1998;63-101.
3. Baldessarini R.J., Huston-Lyons D., Campbell A., Marsh E., Cohen B.M. Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br. J. Psychiatry. 160:1992;12-16.
4. Baumgold J., Dyer K., Falcone J.F., Bymaster F.P. Comparison of second messenger responses to muscarinic receptor stimulation in M1-transfected A9 L cells. Cell. Signal. 7:1995;39-43.
5. Beasley, C.M., Tollefson, G.D., Tran, P., Satterlee, W., Sanger, T., Holman, S. and the olanzapine HGAD Study Group, 1996. Olanzapine versus placebo and haloperidol: acute phase results of the North American double blind olanzapine trial. Neuropsychopharmacology 14, 111-123.
6. Breier A., Buchanan R.W., Waltrip II R.W., Listwak S., Holmes C., Goldstein D.S. The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacology. 10:1994;1-7.
7. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96.
8. 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology. 124:1996;87-94.
9. Bymaster F.P., Li X.-M., Carter P.A., Wong D.T., Perry K.W. Olanzapine increases extracellular dopamine release and blocks dopamine, serotonin and muscarinic receptors in vivo. Schizophr. Res. 24:1997;74.
10. Bymaster F.P., Rasmussen K., Calligaro D.O., Nelson D.L., DeLapp N.W., Wong D.T., Moore N.A. In vitro and In vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J. Clin. Psychiatry. 58(Suppl. 10):1997;28-36.
11. Calligaro D.O., Fairhurst J., Hotten M.H., Moore N.A., Tupper D.E. The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine (LY170053). Biol. Med. Chem. Lett. 7:1997;25-30.
12. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3090-3108.
13. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology. 120:1995;67-74.
14. 3 muscarinic receptors in rat parotid gland couple to two second messenger systems. Am. J. Physiol. 261 (Cell Physiol 30), C1063-C1073.
15. De Lean A., Munson P., Rodbard D. Simultaneous analysis of families of sigmoidal cures: application to bioassay, radioligand assay and physiological dose-response curves. Am. J. Physiol. 235:1978;E97-E102.
16. 2-like' agonist RU 24213. Psychopharmacology. 124:1996;40-49.
17. Donaldson J., Hill S.J. 1,4-Dithiothreitol-induced changes in histamine H1-agonist efficacy and affinity in the longitudinal smooth muscle of guinea-pig ileum. Br. J. Pharmacol. 90:1987;263-271.
18. Dorje F., Wess J., Lambrecht G., Tacke R., Mutschler E., Brann M.R. Antagonist binding profiles of five cloned muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 256:1991;727-733.
19. 2 by inducing calcium influx and activation of protein kinase C. J. Pharmacol. Exp. Ther. 255:1990;1140-1147.
20. Felder C.C., Williams H.L., Axelrod J. A transduction pathway associated with receptors coupled to the inhibitory guanine nucleotide binding protein Gi that amplifies ATP-mediated arachidonic acid release. Proc. Natl. Acad. Sci. USA. 88:1991;6477-6480.
21. Fuller R.W., Snoddy H.D., Perry K.W. Effect of prazosin on norepinephrine concentration and turnover in rat brain and heart. Arch. Int. Pharmacodyn. Ther. 231:1978;30-41.
22. Fuller R.W., Snoddy H.D. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine, an antipsychotic drug candidate. Res. Commun. Chem. Pathol. Pharmacol. 77:1992;87-93.
23. Hemrick-Luecke S.K., Snoddy H.D., Fuller R.W. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sci. 55:1994;479-483.
24. Hippius H. The history of clozapine. Psychopharmacology. 99:1989;S3-S5.
25. Jones S.V.P., Heilman C.J., Brann M.R. Functional responses of cloned muscarinic receptors expressed in CHO cells. Mol. Pharmacol. 40:1991;242-247.
26. Knepper S.M., Buckner S.A., Brune M.E., DeBernardis J.F., Meyer M.D., Hancock A.A. A-61603, a potent alpha 1-adrenergic receptor agonist, selective for the alpha 1A receptor subtype. J. Pharmacol. Exp. Ther. 274:1995;97-103.
27. 35S ]-GTPγS binding mediated by human muscarinic m1-m4 receptors: antagonist studies Br. J. Pharmacol. 109:1993;1120-1127.
28. Levey A.I. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 52:1993;441-448.
29. Li X.-M., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology. 136:1998;153-161.
30. 2 receptor subfamily. Life Sci. 59:1996;1081-1095.
31. Marshall I., Burt R.P., Green G.M., Hussain M.B., Chapple C.R. Different subtypes of alpha 1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053. Br. J. Pharmacol. 119:1996;407-415.
32. McGeer P.L., Grewaal D.S., McGeer E.G. Influence of noncholinergic drugs on rat striatal acetylcholine levels. Brain Res. 80:1974;211-217.
33. Meek J.L., Neff N.H. The rate of formation of 3-methoxy-4-hydroxyphenylethyleneglycol sulfate in brain as an estimate of the rate of formation of norepinephrine. J. Pharmacol. Exp. Ther. 184:1973;570-575.
34. 2 pKi values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
35. Moghaddam B., Bunney B.S. Utilization of microdialysis for assessing the release of mesotelencephalic dopamine following clozapine and other antipsychotic drugs. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 14:1990;S51-S57.
36. Moghaddam B. Preferential activation of cortical dopamine neurotransmission by clozapine: functional significance. J. Clin. Psychiatry. 55(9, Suppl. B):1994;27-29.
37. Moore N.A., Tye N.C., Axton M.S., Risius F.C. The behavioral pharmacology of olanzapine a novel 'atypical' antipsychotic agent. J. Pharmacol. Exp. Ther. 262:1992;545-551.
38. Moore N.A., Calligaro D.O., Wong D.T., Bymaster F.P., Tye N.C. The pharmacology of olanzapine and other new antipsychotic agents. Curr. Opin. Invest. Drugs. 2:1993;281-293.
39. Olianas M.C., Maulla C., Onali P. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor. Br. J. Pharmacol. 122:1997;401-408.
40. Peralta E.G., Ashkenazi A., Winslow J.W., Ramachandran J., Capon D.J. Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature (Lond.). 334:1988;434-437.
41. Przegalinski E., Kordecka-Magiera A., Mogilnicka E., Maj J. Chronic treatment with some atypical antidepressants increases the brain level of 3-methoxy-4-hydroxyphenylglycol (MHPG) in rats. Psychopharmacology. 74:1981;187-190.
42. 2 binding affinity. Neuropsychopharmacology. 1:1988;101-107.
43. Richards M.H., van Giersbergen P.L.M. Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists. Br. J. Pharmacol. 114:1995;1241-1249.
44. 1 properties of 4-(mono- and dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothienol[2,3-c]pyridine analogue. J. Med. Chem. 30:1987;1454-1458.
45. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J. Jr., Shen Y., Meltzer H.Y., Sibley D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 268:1994;1403-1410.
46. Sawaguchi T., Goldman-Rakic P.S. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of Rhesus monkeys performing an oculomotor delayed-response task. J. Neurophysiol. 71:1994;515-528.
47. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
48. 35S ]thio]-triphosphate binding Proc. Natl. Acad. Sci. USA. 92:1995;7242-7246.
49. Stanton T., Bolden-Watson C., Cusack B., Richelson E. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. Biochem. Pharmacol. 45:1993;2352-2354.
50. 2 receptor antagonists-potential in the treatment of psychiatric disorders. Drug Ther. 5:1997;388-409.
51. Stoof J., Kebabian J. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature. 294:1981;366-368.
52. 1-adrenoreceptor antagonism. J. Clin. Psychopharmacology. 15(Suppl. 1):1995;11S-18S.
53. Taylor N., Beuzen J.N., Wesnes K., Wood A. The effect of olanzapine on cognition and psychomotor function in healthy elderly volunteers. Schizophr. Res. 18:1996;131.
54. Tollefson G.D., Sanger T.M., Lu Y., Thieme M.E. Depressive signs and symptoms in schizophrenia - a prospective blinded trial of olanzapine and haloperidol. Arch. Gen. Psychiatry. 55:1998;250-258.
55. 1D receptor subtypes J. Rec. Signal Transduct. Res. 15:1995;199-211.
56. Umezu K., Moore K.E. Effects of drugs on regional brain concentrations of dopamine and dihydroxyphenylacetic acid. J. Pharmacol. Exp. Ther. 208:1979;49-56.
57. 2F receptor. Mol. Pharmacol. 43:1993;419-426.
58. Wainscott D.B., Lucaites V.L., Kursar J.D., Baez M., Nelson D.L. Pharmacological characterization of the human 5-hydroxytryptamine 2B receptor: evidence for species differences. J. Pharmacol. Exp. Ther. 276:1996;720-727.
59. Yamamoto B.K., Pehek E.A., Meltzer H.Y. Brain region effects of clozapine on amino acid and monoamine transmission. J. Clin. Psychiatry. 55(Suppl. B):1994;8-14.
60. Zeng X.P., Le F., Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur. J. Pharmacol. 321:1997;349-354.
61. Zetterstrom T., Sharp T., Ungerstedt U. Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. Eur. J. Pharmacol. 106:1985;27-37.
62. Zorn S.H., Jones S.B., Ward K.M., Liston D.R. Clozapine is a potent and selective muscarinic M4 receptor agonist. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 269:1994;R1-R2.